Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation

Refernces

• Ahima, R.S., 2007. Insulin resistance: cause or consequence of nonalcoholic steatohepatitis. GastroentCerology, 132, 444–446.
   PubMed Web of Science ®Google Scholar
• Angulo, P., et al., 2004. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. Journal of hepatology, 41, 943–949.
   PubMed Web of Science ®Google Scholar
• Banks, A.S., et al., 2000. Activation of downstream signals by the long form of the leptin receptor. Journal of biological chemistry, 275, 4563–4572.
   Web of Science ®Google Scholar
• Bellone, S., et al., 2012. Acylated and unacylated ghrelin levels in normal weight and obese children: influence of puberty and relationship with insulin, leptin and adiponectin levels. Journal of endocrinological investigation 35, 191–197.
   PubMed Web of Science ®Google Scholar
• Blaak, E.E., 2003. Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proceedings of the nutrition society, 62, 753–760.
   PubMed Web of Science ®Google Scholar
• Bresciani, E., et al., 2006. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. Journal of endocrinological investigation, 29, 2–4.
   PubMed Web of Science ®Google Scholar
• Brunt, E.M., 2004. Nonalcoholic steatohepatitis. Seminars in liver disease, 24, 3–20.
   PubMed Web of Science ®Google Scholar
• Buettner, R., et al., 2006. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. Journal of molecular endocrinology, 36, 485–501.
   PubMed Web of Science ®Google Scholar
• Chabrolle, C., Tosca, L., and Dupont, J., 2007. Regulation of adiponectin and its receptors in rat ovary by human chorionic gonadotrophin treatment and potential involvement of adiponectin in granulosa cell steroidogenesis. Reproduction (Cambridge, England), 133, 719–731.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., et al., 2003. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis. American journal of gastroenterology, 98, 2771–2776.
   PubMed Web of Science ®Google Scholar
• Charlton, M., 2007. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. American journal of gastroenterology, 102, 409–411.
   PubMed Web of Science ®Google Scholar
• Chartrel, N., et al., 2007. Comment on “obestatin”, a peptide encoded by the Ghrelin gene, opposes Ghrelin’s effects on food intake. Science, 80, 315–766.
   Google Scholar
• Cohen, B.N.D. and Rubinstein, M., 1996. Modulation of insulin activities by leptin. Science (New York, N.Y.), 274, 1185–1188.
   PubMed Web of Science ®Google Scholar
• De Luca, C. and Olefsky, J.M., 2008. Inflammation and insulin resistance. FEBS Letters, 582, 97–105.
   PubMed Web of Science ®Google Scholar
• Delhanty, P.J., et al., 2010. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One, 5, e11749.
   PubMed Web of Science ®Google Scholar
• Eman, F.K., Ghada, A.A., and Dalia, G.M., 2017. Resveratrol improves high fat diet-induced fatty liver and insulin resistance by concomitant inhibiting proteolytic cleavage of sterol binding elements –binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption. Canadian journal of physiology and pharmacology, 4, 1–13.
   Google Scholar
• Estep, M., et al., 2011. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obesity surgery, 21, 1750–1757.
   PubMed Web of Science ®Google Scholar
• Folch, J., Lees, M., and Sobane, S., 1957. A simple method for isolation and purification of total lipid from animal tissues. Journal of biological chemistry, 226, 497–509.
   PubMed Web of Science ®Google Scholar
• Fraulob, J.C., et al., 2010. A mouse model of metabolic syndrome: insulin resistance, fatty liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 mice fed a high fat diet. Journal of clinical biochemistry and nutrition, 46, 212–223.
   PubMed Web of Science ®Google Scholar
• Gauna, C., et al., 2004. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. Journal of clinical endocrinology and metabolism, 89, 5035–5042.
   PubMed Web of Science ®Google Scholar
• Gauna, C., et al., 2005. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. Journal of clinical endocrinology and metabolism, 90, 1055–1060.
   PubMed Web of Science ®Google Scholar
• Gauna, C., et al., 2007. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. American journal of physiology- endocrinology and metabolism, 293, E697–E704.
   PubMed Web of Science ®Google Scholar
• González, C.R., et al., 2008. Influence of chronic undernutrition and leptin on GOAT mRNA levels in rat stomach mucosa. Journal of molecular endocrinology, 41, 415–421.
   PubMed Web of Science ®Google Scholar
• Gourcerol, G., et al., 2006. Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signaling in rodents. Peptides, 27, 2811–2819.
   PubMed Web of Science ®Google Scholar
• Granata, R., et al., 2012. Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB journal : official publication of the federation of American societies for experimental biology, 26, 3393–3411.
   PubMed Web of Science ®Google Scholar
• Granata, R., et al., 2008. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes, 57, 967–979.
   PubMed Web of Science ®Google Scholar
• Granata, R., et al., 2010. Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. Journal of molecular endocrinology, 45, 9–17.
   PubMed Web of Science ®Google Scholar
• Green, B.D., Irwin, N., and Flatt, P.R., 2007. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides, 28, 981–987.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Grobe, Y., et al., 2010. High ghrelin and obestatin levels and low risk of developing fatty liver. Annals of hepatology, 9, 52–57.
   PubMed Web of Science ®Google Scholar
• Hosoda, H., et al., 2004. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clinical chemistry, 50, 1077.
   PubMed Web of Science ®Google Scholar
• Jaeschke, H. and McCuskey, R.S., 2004. The importance of leptin in mice and man. Journal of hepatology, 40, 359–361.
   Web of Science ®Google Scholar
• Javor, E.D., et al., 2005. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology, 41, 753–760.
   PubMed Web of Science ®Google Scholar
• Kelley, D.E., et al., 2003. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. American journal of physiology- endocrinology and metabolism, 285, E906–E916.
   PubMed Web of Science ®Google Scholar
• Kołodziejski, P.A., et al., 2017. Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function. Endocrine, 56, 538–550.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2013. Impairment of reproductive function in a male rat model of non-alcoholic fatty liver disease and beneficial effect of N-3 fatty acid supplementation. Toxicology letters, 222, 224–232.
   PubMed Web of Science ®Google Scholar
• Lieber, C.S., et al., 2004. Model of nonalcoholic steatohepatitis. American journal of clinical nutrition, 79, 502–509.
   PubMed Web of Science ®Google Scholar
• Lutchman, G., et al., 2006. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clinical gastroenterology and hepatology, 4, 1048–1052.
   PubMed Web of Science ®Google Scholar
• Machado, M. and Cortez, P.H., 2005. Non-alcoholic fatty liver disease and insulin resistance. European journal of gastroenterology & hepatology, 17, 823–836.
   PubMed Web of Science ®Google Scholar
• Marchesini, G., et al., 2003. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. Journal of clinical endocrinology and metabolism, 88, 5674–5679.
   PubMed Web of Science ®Google Scholar
• Mather, K., 2009. Surrogate measures of insulin resistance: of rats, mice, and men. American journal of physiology- endocrinology and metabolism, 296, E398–E399.
   PubMed Web of Science ®Google Scholar
• Mehta, K., et al., 2002. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutrition Reviews, 60, 289–293.
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez, N., et al., 2005. Adiponectin as a protective factor in hepatic steatosis. World journal of gastroenterology, 11, 1737–1741.
   PubMed Web of Science ®Google Scholar
• Michael, E., et al., 2010. Serum obestatin concentrations in non-alcoholic fatty liver disease (NAFLD) with fibrosis. Gastroenterology, 38, S802.
   Google Scholar
• Musso, G., et al., 2005. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology , 42, 1175–1183.
   PubMed Web of Science ®Google Scholar
• Nakajima, K., 2012. Multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease. International journal of hepatology, 2012, 950693.
   PubMedGoogle Scholar
• Nishi, Y., et al., 2005. Ingested medium-chain fatty acids are directly utilized for the acyl modification of ghrelin. Endocrinology, 146, 2255–2264.
   PubMed Web of Science ®Google Scholar
• Polyzos, S.A., et al., 2010. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes, obesity & metabolism, 12, 365–383.
   PubMed Web of Science ®Google Scholar
• Polyzos, S.A., et al., 2016. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 59, 30–43.
   PubMed Web of Science ®Google Scholar
• Rector, R.S., et al., 2008. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World journal of gastroenterology, 14, 185–192.
   PubMed Web of Science ®Google Scholar
• Ren, A.J., et al., 2009. Obestatin, obesity and diabetes. Peptides, 30, 439–444.
   PubMed Web of Science ®Google Scholar
• Rodríguez, A., et al., 2009. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. International journal of obesity 33, 541–552.
   PubMed Web of Science ®Google Scholar
• Rodríguez, A., et al., 2012. The ghrelin o-acetyltransferase-ghrelin system reduces TNF-α and autophagy in human visceral adipocytes. Diabetologia, 55, 3038–3050.
   PubMed Web of Science ®Google Scholar
• Sasidharan, S., et al., 2014. Ameliorative potential of tamarindus indica on high fat diet induced nonalcoholic fatty liver disease in rats. Scientific world journal, 2014, 507197.
   Google Scholar
• Smolinski, D.J., et al., 2007. Additional nuclei and NOR activity during meiotic prophase 1in Irch(Larix decidua Mill). Protoplasm, 232, 109–120.
   PubMed Web of Science ®Google Scholar
• St-Pierre, D.H., et al., 2007. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. Journal of clinical endocrinology and metabolism, 92, 264–269.
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni, G., et al., 2006. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. The American journal of pathology, 169, 846–860.
   PubMed Web of Science ®Google Scholar
• Tsochatzis, E., Papatheodoridis, G.V., and Archimandritis, A.J., 2006. The evolving role of leptin and adiponectin in chronic liver diseases. The American journal of gastroenterology, 101, 2629–2640.
   PubMed Web of Science ®Google Scholar
• Van der Lely, A.J., et al., 2004. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrine reviews, 25, 426–457.
   PubMed Web of Science ®Google Scholar
• Vuguin, P., et al., 2004. Hepatic insulin resistance precedes the development of diabetes in a model of intrauterine growth retardation. Diabetes, 53, 2617–6722.
   PubMed Web of Science ®Google Scholar
• Wang, Y.U., et al., 2009. Protective roles of adiponectin in obesity related fatty liver diseases: mechanisms and therapeutic implications. Arquivos brasileiros de endocrinologia & metabologia, 53, 201–212.
   PubMedGoogle Scholar
• Wang, W., et al., 2013. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver. PloS One, 8, e76538.
   PubMed Web of Science ®Google Scholar
• Weyer, C., et al., 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of clinical endocrinology and metabolism, 86, 1930–1935.
   PubMed Web of Science ®Google Scholar
• Wiedmer, P., et al., 2007. Ghrelin, obesity and diabetes. Nature clinical practice endocrinology & metabolism, 3, 705–712.
   PubMedGoogle Scholar
• Wulster-Radcliffe, M.C., et al., 2004. Adiponectin differentially regulates cytokines in porcine macrophages. Biochemical and biophysical research communications, 316, 924–929.
   PubMed Web of Science ®Google Scholar
• Yamanaka, O., et al., 2006. Interleukin-7 modulates extracellular matrix production and TGF-beta signaling in cultured human subconjunctival fibroblasts. Current eye research, 31, 491–499.
   PubMed Web of Science ®Google Scholar
• Yokota, T., et al., 2002. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96, 1723–1732.
   Web of Science ®Google Scholar
• Zhang, J.V., et al., 2005. Obestatin, a peptide encoded by the Ghrelin gene, opposes ghrelin's effects on food intake. Science , 310, 996–999.
   PubMed Web of Science ®Google Scholar
• Zizzari, P., et al., 2007. Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology, 148, 1648–1653.
   PubMed Web of Science ®Google Scholar